Sanofi S.A., FR0000120578

Sanofi stock: Berenberg sets EUR 105.00 target for Sanofi stock

Published on 10/19/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 30, 2026. Sanofi stock costs EUR 71.22 on October 19, 2026, minus 0.99 percent versus the Xetra close.

Analyst target and reporting date

On October 16, 2026, Berenberg Bank analyst Luisa Hector set a EUR 105.00 target for Sanofi.
Sanofi will present third-quarter 2026 results on October 30, 2026.
Sanofi stock costs EUR 71.22 at Lang & Schwarz on October 19, 2026 at 3:35 p.m. CEST, minus 0.99 percent versus the Xetra close of October 16, 2026.
Sanofi has a price-to-earnings ratio of 21.94 as of October 19, 2026.

Architectural visualization render of a futuristic pharmaceutical laboratory building with cleanroom airlocks, floor-to-ceiling glass walls and violet-blue accent lighting — Sanofi FR0000120578 architectural CGI render of multi-story high-tech pharmaceutical laboratory with cleanroom airlock entry, Illustration mit AI erstellt.

Berenberg Bank analyst Luisa Hector maintained a Buy rating and set a EUR 105.00 target for Sanofi on October 16, 2026, according to The Globe and Mail. The target stands 47.41 percent above Sanofi's EUR 71.22 price at Lang & Schwarz on October 19, 2026 at 3:35 p.m. CEST. The stock was 0.99 percent below the Xetra close of October 16, 2026.

Sanofi will present its third-quarter 2026 results on October 30, 2026, with a management presentation and question-and-answer session from 1:30 p.m. to 2:30 p.m. CET, according to Sanofi. That date gives the market a defined checkpoint after the recent target revision.

Trading range sets the frame

The Lang & Schwarz bid was EUR 71.21 and the ask was EUR 71.23 at 3:35 p.m. CEST on October 19, 2026. Volume on the primary listing stood at 552,255 shares, compared with an average of 2,042,370 shares, or 27.04 percent of that average.

Sanofi's 52-week range was EUR 69.75 to EUR 91.15 as of October 19, 2026. The stock stood 2.11 percent above its low and 21.87 percent below its high, putting the current quote materially nearer the lower end of the range.

Valuation and reporting date

Sanofi's market capitalization was EUR 85.1 billion and its price-to-earnings ratio was 21.94 as of October 19, 2026. The scheduled October 30 results are the next company date listed for investors, while the October 16 target from Berenberg provides the latest named valuation reference in this report.

Comparison with peers

Sanofi: minus 0.99 percent, P/E 21.94, market capitalization EUR 85.1 billion.

GSK (NYSE, USD): plus 0.08 percent, P/E 15.67, market capitalization USD 99.3 billion.

AstraZeneca (Nasdaq, USD): minus 0.25 percent, P/E 24.77, market capitalization USD 255.9 billion.

Stock position after October 16

The latest market picture combines a target of EUR 105.00 from Berenberg with a quote close to Sanofi's 52-week low. The October 30 reporting date is the next scheduled event that can test the assumptions behind the target.

Sanofi was trading at EUR 71.22 at Lang & Schwarz on October 19, 2026 at 3:35 p.m. CEST, minus 0.99 percent versus the Xetra close of October 16, 2026 at EUR 71.93. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.